SHIN1 RZ-2994 is an investigational drug being developed for the treatment of cancer. It is a selective inhibitor of serine hydroxymethyltransferase 1 (SHMT1), an enzyme involved in the one-carbon metabolism pathway that plays a role in DNA synthesis and cell proliferation. The chemical name for SHIN1 RZ-2994 is (1S,3aR,4S,6R)-2-amino-1,3,3a,4-tetrahydro-4-hydroxy-6-(hydroxymethyl)cyclopenta[c]pyran-1-carboxylic acid, and its molecular formula is C10H17NO5. Its molecular weight is 231.25 g/mol, and the CAS number for this compound is 2146095-85-2.
Top Ten Keywords and Synonyms
Health Benefits of SHIN1 RZ-2994 SHIN1 RZ-2994 has shown promising results in preclinical studies as a potential treatment for various types of cancer, including breast, lung, and colon cancer. It may offer selective targeting of SHMT1, leading to inhibition of tumor growth and cell proliferation. Its novel mechanism of action may provide an alternative for patients who have failed other treatments.
Potential Effects of SHIN1 RZ-2994 SHIN1 RZ-2994 works by selectively inhibiting the activity of SHMT1, an enzyme involved in the one-carbon metabolism pathway that plays a role in DNA synthesis and cell proliferation. By doing so, it can potentially inhibit tumor growth and cell proliferation and sensitize cancer cells to other therapies. In preclinical studies, SHIN1 RZ-2994 has demonstrated antiproliferative effects in various types of cancer.
Product Mechanism SHIN1 RZ-2994 is a selective inhibitor of serine hydroxymethyltransferase 1 (SHMT1), an enzyme involved in the one-carbon metabolism pathway that plays a role in DNA synthesis and cell proliferation. By inhibiting SHMT1, SHIN1 RZ-2994 can potentially inhibit tumor growth and cell proliferation and sensitize cancer cells to other therapies.
Safety SHIN1 RZ-2994 is still undergoing clinical trials, and its safety profile has not yet been fully established. However, preclinical studies and early-stage clinical trials suggest that it may be well-tolerated and safe for use in cancer patients. Ongoing clinical trials will continue to evaluate the safety and efficacy of SHIN1 RZ-2994.
Side Effects The potential side effects of SHIN1 RZ-2994 are not yet fully known, as it is still undergoing clinical trials. However, common side effects of other molecular targeted therapies include fatigue, nausea, vomiting, diarrhea, and decreased appetite. Patients should seek medical attention if they experience any symptoms of these conditions.
Dosing Information The optimal dosage of SHIN1 RZ-2994 for the treatment of cancer is still being determined through ongoing clinical trials. Patients should follow their healthcare professional's instructions for dosing and administration.
Conclusion In conclusion, SHIN1 RZ-2994 is an investigational drug being developed for the treatment of various types of cancer. It is a selective inhibitor of SHMT1, which plays a role in the one-carbon metabolism pathway involved in DNA synthesis and cell proliferation. Although its safety profile has not yet been fully established, early indications suggest that it may be well-tolerated and safe for use in cancer patients. Its development highlights the ongoing efforts to develop more effective and targeted treatments for patients with cancer. If approved, SHIN1 RZ-2994 may provide a new therapeutic option for patients who have failed other treatments.
